The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant

Active:	Yes
Cancer Type:	Cancer-Related Syndrome Hematopoietic Malignancies Leukemia Lymphoma Multiple Myeloma Myelodysplastic Syndromes (MDS) Plasma cell neoplasm	NCT ID:	NCT03805789
Trial Phases:	Phase II Phase III	Protocol IDs:	CSL964_2001 (primary) NCI-2019-03310 2018-000329-29
Eligibility:	12 Years and older, Male and Female	Study Type:	Prevention
Study Sponsor:	CSL Behring
NCI Full Details:	http://clinicaltrials.gov/show/NCT03805789

Summary

This study is a phase 2 / 3 prospective, double-blind, randomized, multicenter,
placebo-controlled study for prevention of acute GVHD (aGVHD) in participants undergoing
an unrelated (matched or single allele mismatched) or matched related allogeneic
hematopoietic cell transplantation (HCT).

Treatment Sites in Georgia

Emory University Hospital - Atlanta
1364 Clifton Road NE
Atlanta, GA 30322
www.emoryhealthcare.org

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.